Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IASO207 in active refractory systemic lupus erythematosus
NCT07617740Phase 1Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- May 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IASO207 in systemic lupus erythematosus (SLE), sponsored by Peking University People's Hospital. Primary endpoints: Adverse Events at 2 years and Dose-Limiting Toxicity at 28 days. Started May 2026; status: recruiting.
02
Drugs
IASO207
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07617740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07617740.